# Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency

> **NCT01322477** · — · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 25 (—)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **OTHER:** F18-FDG PET/CT

## Key facts

- **NCT ID:** NCT01322477
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 25 (—)
- **Last updated:** 2011-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01322477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01322477, "Contribution of F-18 Fluoro-Deoxy-Glucose PET/CT (Positron Emission Tomography) to the Assessment of HCC (Hepato-cellular Carcinoma) Treatment Efficiency". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01322477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*